文献速递白血病

B淋巴母细胞白血病中PIGH表达的表观下调导致GPI锚丢失

Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression.
PubMed 文献 · Am J Hematol · 2018-11-25

成人B淋巴母细胞白血病(B-ALL)存在遗传异质性,缓解后常因耐药亚克隆生长而复发。本研究发现B-ALL患者诊断时即常存在小的GPI锚缺陷CD52阴性B细胞群,其他B细胞恶性肿瘤患者则无;该表型源于PIGH基因mRNA表达丢失(GPI锚合成第一步),系表观沉默而非基因突变或缺失;CD52膜表达缺失可能促进阿仑单抗(ALM)耐药及CD52阴性逃逸变体生长,加用5-aza-2'-脱氧胞苷可能恢复CD52表达并逆转ALM耐药。

要点

  • B-ALL诊断时即可检出小的GPI锚缺陷CD52阴性B细胞群,其他B细胞恶性肿瘤未见。
  • GPI锚阴性表型源于PIGH基因mRNA表达丢失,系表观沉默而非基因突变或缺失。
  • CD52膜表达缺失可能促进ALM耐药及CD52阴性逃逸变体生长,加用5-aza-2'-脱氧胞苷可能恢复CD52表达并逆转ALM耐药。

核心结论

  • B-ALL患者诊断时即常存在小的GPI锚缺陷CD52阴性B细胞群,其源于PIGH基因mRNA表观沉默而非基因突变或缺失,CD52膜表达缺失可能促进ALM耐药和CD52阴性逃逸变体生长,加用5-aza-2'-脱氧胞苷可能恢复CD52表达并逆转ALM耐药。

研究设计与样本

  • 本研究为实验研究,纳入成人B-ALL患者及其他B细胞恶性肿瘤患者,比较GPI锚缺陷CD52阴性B细胞群的存在情况,并分析PIGH基因mRNA表达、表观沉默机制及ALM耐药与5-aza-2'-脱氧胞苷干预效果。

主要发现

  • B-ALL患者诊断时即常存在小的GPI锚缺陷CD52阴性B细胞群,其他B细胞恶性肿瘤患者则无。
  • GPI锚阴性表型源于PIGH基因mRNA表达丢失,该基因参与GPI锚合成第一步。
  • B-ALL细胞中PIGH mRNA表达丢失系表观沉默而非基因突变或缺失。
  • CD52膜表达缺失可能促进B-ALL患者对ALM耐药,导致CD52阴性逃逸变体生长。
  • 加用5-aza-2'-脱氧胞苷可能恢复CD52表达并逆转ALM耐药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adult B-lymphoblastic leukemia (B-ALL) is a hematological malignancy characterized by genetic heterogeneity. Despite successful remission induction with classical chemotherapeutics and novel targeted agents, enduring remission is often hampered by disease relapse due to outgrowth of a pre-existing subclone resistant against the treatment. In this study, we show that small glycophosphatidylinositol (GPI)-anchor deficient CD52-negative B-cell populations are frequently present already at diagnosis in B-ALL patients, but not in patients suffering from other B-cell malignancies. We demonstrate that the GPI-anchor negative phenotype results from loss of mRNA expression of the PIGH gene, which is involved in the first step of GPI-anchor synthesis. Loss of PIGH mRNA expression within these B-ALL cells follows epigenetic silencing rather than gene mutation or deletion. The coinciding loss of CD52 membrane expression may contribute to the development of resistance to alemtuzumab (ALM) treatment in B-ALL patients resulting in the outgrowth of CD52-negative escape variants. Additional treatment with 5-aza-2'-deoxycytidine may restore expression of CD52 and revert ALM resistance.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Loeff FC, Rijs K, van Egmond EHM, et al. Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression. Am J Hematol. 2018. PMID: 30370942. doi:10.1002/ajh.25337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。